GO
Loading...

Enter multiple symbols separated by commas

AstraZeneca PLC

More

  • LONDON, April 21- AstraZeneca's recently approved ovarian cancer drug Lynparza, or olaparib, can also help men with prostate cancer, according to new clinical trial results on Tuesday. AstraZeneca has flagged olaparib as a potential $2- billion- a-year seller, based on ongoing Phase III studies in ovarian, breast, gastric and pancreatic cancers.

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • LONDON, April 15- European shares hit a 14- year high and the euro fell on Wednesday after the European Central Bank affirmed its loose policy stance and as weak data from China raised prospects of monetary easing there too. Firmer commodity prices and merger news also helped hoist European stocks, and U.S. stock index futures pointed to a firmer start on Wall...

  • LONDON, April 15- European shares hit a 14- year high on Wednesday before a meeting at which the European Central Bank is expected to affirm its loose policy stance, as weak data from China raised prospects of monetary easing there too. Firmer commodity prices and merger news also helped hoist European stocks, and U.S. stock index futures pointed to a firmer start...

  • LONDON, April 15- European shares hit a 14- year high on Wednesday before a meeting at which the European Central Bank is expected to affirm its loose policy stance, as weak data from China raised prospects of monetary easing there too. A banking source told Reuters on Tuesday the ECB raised the cap on emergency liquidity assistance that Greek banks can draw from...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza and Takeda Pharmaceutical Co.' s rival product Nesina should carry information about the risk of heart failure, an advisory committee to the U.S. Food and Drug Administration said on Tuesday. The panel reviewed safety data on AstraZeneca's Onglyza and Takeda's Nesina. The studies were requested by...

  • A preliminary FDA review of Nesina, or alogliptin, showed a numerical increase in heart failure hospitalizations but not a statistically significant increase. Even so, some analysts expect the FDA to treat all drugs in the class the same way. "We believe the FDA will likely view the risk as likely to be a class effect and apply changes to all approved drugs in the...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. A preliminary FDA review of the drug published on Friday noted an...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted overwhelmingly that the drug's label should be changed to add information about an increased heart failure risk, but did not...

  • Demand for newer cancer and multiple sclerosis treatments, price increases on branded medicines, particularly insulin products for diabetes, and the entry of few new generic versions of big-selling drugs also contributed to the double-digit spending rise in 2014, the report by IMS Health Holdings Inc found. "We certainly expect to see growth in the market...

  • UK's FTSE races to new record high as Shire shines Friday, 10 Apr 2015 | 11:59 AM ET

    *FTSE 100 up 1.1 pct at record closing high of 7,089.77. *FTSE rises even though election uncertainty hits pound. *FTSE 100 up 8 pct since start of 2015.

  • April 10- AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug's safety. The FDA said the causes of death...

  • Britain's FTSE nears record high as Shire shines Friday, 10 Apr 2015 | 9:11 AM ET

    *FTSE 100 up 0.5 pct, near record highs. The FTSE 100 rose 0.5 percent to 7,051.07 points, close to a record 7,065.08 points reached in March. Shire shares rose 5.2 percent, the biggest gain on the FTSE 100, from a U.S. Food and Drug Administration decision to grant a priority review to its application for lifitegrast, a dry-eye disease treatment.

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • FRANKFURT, April 1- Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Roche is vying with rivals such as Bristol-Myers Squibb, Merck& Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune...

  • Pay rises may be hard to find - if you’re a FTSE CEO Wednesday, 1 Apr 2015 | 3:09 AM ET
    Smelling money bonus

    Here’s a phrase you don’t hear that often: It’s tough out there for the U.K.’s leading chief executives.

  • Drugs companies unite to mine genetic data Thursday, 26 Mar 2015 | 2:25 AM ET

    Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.